Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: A meta-analysis

Molecular Biology Reports

Volumn 40, Issue 5, 2013, Pages 3597-3608

  Li, Qiaoxin ^a   Zhu, Yao ^a   He, Jing ^a   Wang, Mengyun ^a   Zhu, Meiling ^a   Shi, Tingyan ^a   Qiu, Lixin ^a   Ye, Dingwei ^a   Wei, Qingyi ^a,b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Polymorphism; Prostate cancer; Steroid 5 reductase type 2 (SRD5A2); Susceptibility

Indexed keywords

STEROID 5ALPHA REDUCTASE 2;

ALLELE; ARTICLE; CALCULATION; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CAUCASIAN; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; GENETIC MODEL; HUMAN; META ANALYSIS (TOPIC); PROSTATE CANCER; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; VALIDITY;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RISK;

EID: 84878397597     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2434-x     Document Type: Article

References (64)

1. Crawford ED (2009) Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 73:S4-S10
2. Boger-Megiddo I, Weiss NS, Barnett MJ et al (2008) V89L polymorphism of the 5alpha-reductase type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk. Cancer Epidemiol Biomark Prev 17:286-291
3. Ilic M, Vlajinac H, Marinkovic J (1996) Case-control study of risk factors for prostate cancer. Br J Cancer 74:1682-1686
4. Stacewicz-Sapuntzakis M, Borthakur G, Burns JL et al (2008) Correlations of dietary patterns with prostate health. Mol Nutr Food Res 52:114-130
5. Ferris ITJ, Berbel-Tornero O, Garcia ICJ et al (2011) Nondietetic environmental risk factors in prostate cancer. Actas Urol Esp 35:289-295
6. Tamburrino L, Salvianti F, Marchiani S et al (2012) Androgen receptor (AR) expression in prostate cancer and progression of the tumor: lessons from cell lines, animal models and human specimens. Steroids 77:996-1001
7. Leav I, Lau KM, Adams JY et al (2001) Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159:79-92
8. Cicek MS, Conti DV, Curran A et al (2004) Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 59:69-76
9. Geller J, de la Vega DJ, Albert JD et al (1984) Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer. J Clin Endocrinol Metab 58:36-40
10. Wilbert DM, Griffin JE, Wilson JD (1983) Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab 56:113-120
11. Ross RK, Bernstein L, Lobo RA et al (1992) 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US White and Black males. Lancet 339:887-889
12. Wu AH, Whittemore AS, Kolonel LN et al (1995) Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, White, and Asian men in the United States and Canada. Cancer Epidemiol Biomark Prev 4:735-741
13. Hayes VM, Severi G, Padilla EJ et al (2007) 5Alpha-reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer 120:776-780
14. Makridakis NM, Ross RK, Pike MC et al (1999) Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354:975-978
15. Makridakis NM, Ross RK, Pike MC et al (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 57:1020-1022
16. Nam RK, Zhang WW, Trachtenberg J et al (2003) Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomark Prev 12:1429-1437
17. Febbo PG, Kantoff PW, Platz EA et al (1999) The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res 59:5878-5881
18. Lunn RM, Bell DA, Mohler JL et al (1999) Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 20:1727-1731
19. Yamada Y, Watanabe M, Murata M et al (2001) Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 92:683-686
20. Hsing AW, Chen C, Chokkalingam AP et al (2001) Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomark Prev 10:1077-1082
21. Soderstrom T, Wadelius M, Andersson SO et al (2002) 5Alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 12:307-312
22. Latil AG, Azzouzi R, Cancel GS et al (2001) Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92:1130-1137
23. Pearce CL, Makridakis NM, Ross RK et al (2002) Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol Biomark Prev 11:417-418
24. Margiotti K, Sangiuolo F, De Luca A et al (2000) Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients. Dis Markers 16:147-150
25. Li J, Coates RJ, Gwinn M et al (2010) Steroid 5-{alpha}-reductase type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review. Am J Epidemiol 171:1-13
26. Wang C, Tao W, Chen Q et al (2010) SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis. Prostate 70:170-178
27. Li X, Huang Y, Fu X et al (2011) Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer. Mutagenesis 26:371-383
28. Forrest MS, Edwards SM, Houlston R et al (2005) Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis 8:95-102
29. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820-826
30. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
31. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
32. Wacholder S, Chanock S, Garcia-Closas M et al (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434-442
33. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
34. Cussenot O, Azzouzi AR, Nicolaiew N et al (2007) Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol 52:1082-1087
35. Rajender S, Vijayalakshmi K, Pooja S et al (2009) Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. J Androl 30:703-710
36. Li Z, Habuchi T, Mitsumori K et al (2003) Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol 169:2378-2381
37. Salam MT, Ursin G, Skinner EC et al (2005) Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol 23:246-253
38. Hsing AW (2001) Hormones and prostate cancer: what's next? Epidemiol Rev 23:42-58
39. Ntais C, Polycarpou A, Ioannidis JP (2003) SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomark Prev 12:618-624
40. Vatten LJ, Ursin G, Ross RK et al (1997) Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomark Prev 6:967-969
41. Heinrichs S, Look AT (2007) Identification of structural aberrations in cancer by SNP array analysis. Genome Biol 8:219
42. Hemminki K, Bermejo JL (2005) Relationships between familial risks of cancer and the effects of heritable genes and their SNP variants. Mutat Res 592:6-17
43. Bernig T, Chanock SJ (2006) Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn 6:319-331
44. Scariano JK, Treat E, Alba F et al (2008) The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Prostate 68:1798-1805
45. Nam RK, Toi A, Vesprini D et al (2001) V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 57:199-204
46. Sobti RC, Onsory K, Al-Badran AI et al (2006) CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol 25:287-294
47. Onen IH, Ekmekci A, Eroglu M et al (2007) The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol 26:100-107
48. Chang BL, Zheng SL, Isaacs SD et al (2003) Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. Prostate 56:37-44
49. Zenimoto M, Kita M, Arai T et al (2003) Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer. Rinsho Byori 51:969-973
50. Tochigi T, Kawamura S, Numahata K et al (2001) Retrospective evaluation of PSA density for selection of biopsy candidates with prostate specific antigen in the gray zone. Nihon Hinyokika Gakkai Zasshi 92:609-614
51. Marberger M, Barentsz J, Emberton M et al (2012) Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU Int 109(Suppl 2):1-7
52. Mononen N, Ikonen T, Syrjakoski K et al (2001) A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer 84:1344-1347
53. Lamharzi N, Johnson MM, Goodman G et al (2003) Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer. Int J Cancer 105:480-483
54. Giwercman YL, Abrahamsson PA, Giwercman A et al (2005) The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur Urol 48:679-685
55. Lindstrom S, Wiklund F, Adami HO et al (2006) Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development. Cancer Res 66:11077-11083
56. Berndt SI, Chatterjee N, Huang WY et al (2007) Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomark Prev 16:165-168
57. Cunningham JM, Hebbring SJ, McDonnell SK et al (2007) Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomark Prev 16:969-978
58. Neslund-Dudas C, Bock CH, Monaghan K et al (2007) SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate 67:1654-1663
59. Lindstrom S, Zheng SL, Wiklund F et al (2006) Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 66:1729-1743
60. Sarma AV, Dunn RL, Lange LA et al (2008) Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate 68:296-305
61. Torkko KC, van Bokhoven A, Mai P et al (2008) VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res 14:3223-3229
62. Kantoff PW, Febbo PG, Giovannucci E et al (1997) A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol Biomark Prev 6:189-192
63. Pearce CL, Van Den Berg DJ, Makridakis NM et al (2008) No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Hum Mol Genet 17:2456-2461
64. Sobti RC, Gupta L, Singh SK et al (2008) Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer Genet Cytogenet 185:78-85